MoonLake Immunotherapeutics Target of Unusually Large Options Trading (NASDAQ:MLTX)

MoonLake Immunotherapeutics (NASDAQ:MLTX) was the recipient of unusually large options trading activity on Thursday. Traders acquired 9,628 call options on the stock. This represents an increase of approximately 52% compared to the typical volume of 6,322 call options.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on MLTX shares. Weiss Ratings restated a “sell (d-)” rating on shares of MoonLake Immunotherapeutics in a research report on Wednesday, October 8th. HC Wainwright lowered their price objective on MoonLake Immunotherapeutics from $30.00 to $26.00 and set a “buy” rating for the company in a research report on Friday, November 21st. Stifel Nicolaus downgraded shares of MoonLake Immunotherapeutics from a “buy” rating to a “hold” rating and set a $13.00 target price on the stock. in a research report on Monday, September 29th. Wolfe Research lowered shares of MoonLake Immunotherapeutics from an “outperform” rating to an “underperform” rating in a research note on Tuesday, September 30th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $7.00 price target on shares of MoonLake Immunotherapeutics in a research report on Wednesday, October 1st. Five equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $30.25.

Insider Transactions at MoonLake Immunotherapeutics

In other MoonLake Immunotherapeutics news, major shareholder Bihua Chen sold 6,494,151 shares of the stock in a transaction on Monday, September 29th. The stock was sold at an average price of $7.21, for a total value of $46,822,828.71. Following the transaction, the insider directly owned 2,000,000 shares in the company, valued at approximately $14,420,000. This trade represents a 76.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 12.02% of the company’s stock.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Several hedge funds have recently bought and sold shares of the company. Bank of America Corp DE boosted its position in shares of MoonLake Immunotherapeutics by 64.7% during the third quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock worth $32,000 after purchasing an additional 1,781 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in MoonLake Immunotherapeutics by 115.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock worth $42,000 after buying an additional 3,166 shares during the period. Covestor Ltd bought a new position in MoonLake Immunotherapeutics during the third quarter worth about $46,000. BNP Paribas Financial Markets lifted its holdings in MoonLake Immunotherapeutics by 18.9% during the third quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company’s stock worth $52,000 after acquiring an additional 1,158 shares in the last quarter. Finally, Quarry LP grew its stake in MoonLake Immunotherapeutics by 400.1% in the third quarter. Quarry LP now owns 9,001 shares of the company’s stock valued at $65,000 after acquiring an additional 7,201 shares during the period. 93.85% of the stock is currently owned by institutional investors and hedge funds.

MoonLake Immunotherapeutics Price Performance

Shares of MLTX opened at $14.90 on Friday. The stock has a market cap of $957.03 million, a P/E ratio of -4.49 and a beta of 1.21. MoonLake Immunotherapeutics has a 1 year low of $5.95 and a 1 year high of $62.75. The stock’s 50-day moving average price is $10.88 and its two-hundred day moving average price is $36.62. The company has a current ratio of 8.50, a quick ratio of 8.50 and a debt-to-equity ratio of 0.25.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($1.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.21). During the same quarter last year, the business posted ($0.56) EPS. On average, equities analysts predict that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.